-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
H6D:F:F- (EUR)
COMMON STOCK | Drug Manufacturers - Specialty & Generic |
Last Closing
USD 7.8Change
-0.05 (-0.64)%Market Cap
USD 36.53BVolume
900.00N/A
Verdict
Values as of: 2024-06-26
COMMON STOCK | Drug Manufacturers - Specialty & Generic |
Last Closing
USD 7.8Change
-0.05 (-0.64)%Market Cap
USD 36.53BVolume
900.00N/A
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ZOE:F | Zoetis Inc |
N/A |
USD 74.98B |
MRK:F | Merck & Company Inc |
N/A |
USD 67.63B |
MRKC:F | MERCK KGAA NAM.SP.ADR |
N/A |
USD 66.75B |
TKD:F | Takeda Pharmaceutical Company .. |
N/A |
USD 38.24B |
TKDA:F | Takeda Pharmaceutical Company .. |
N/A |
USD 37.78B |
H6D0:F | Haleon PLC |
N/A |
USD 36.51B |
TEV:F | Teva Pharmaceutical Industries.. |
N/A |
USD 17.71B |
3KY:F | HANSOH PHARMAC. HD-00001 |
N/A |
USD 12.77B |
NB3:F | Neurocrine Biosciences Inc |
N/A |
USD 12.72B |
RDDA:F | Dr. Reddy's Laboratories Limit.. |
N/A |
USD 10.99B |
N/A
Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 9.86% | 59% | D- | 67% | D+ | ||
Dividend Return | 1.50% | 18% | F | 28% | F | ||
Total Return | 11.36% | 55% | F | 63% | D | ||
Trailing 12 Months | |||||||
Capital Gain | 9.86% | 61% | D- | 61% | D- | ||
Dividend Return | 1.75% | 26% | F | 17% | F | ||
Total Return | 11.61% | 56% | F | 56% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 4.16% | 74% | C | 59% | D- | ||
Dividend Return | 4.40% | 69% | C- | 54% | F | ||
Total Return | 0.24% | 20% | F | 13% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 8.75% | 94% | A | 88% | B+ | ||
Risk Adjusted Return | 50.27% | 83% | B | 74% | C | ||
Market Capitalization | 36.53B | 98% | N/A | 95% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.